Ribociclib (LEE011) Rollover Study for Continued Access
Trial Status: Active
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Inclusion Criteria
- Patient is currently enrolled in an eligible Novartis-sponsored study and receiving ribociclib (LEE011) as single agent or in combination with other investigational treatment.
- Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator.
Exclusion Criteria
- Patient has been permanently discontinued from ribociclib (LEE011) in the parent protocol for any reason.
- Patients who do not meet parent protocol criteria to continue study treatment.
Alabama
Birmingham
University of Alabama at Birmingham Cancer Center
Status: CLOSED_TO_ACCRUAL
Michigan
Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: COMPLETED
New York
Bronx
Montefiore Medical Center-Weiler Hospital
Status: ACTIVE
Tennessee
Memphis
Saint Jude Children's Research Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Giles W. Robinson
Phone: 901-595-2907
Email:
giles.robinson@stjude.org
Trial Phase Phase II
Trial Type Treatment
Lead Organization
Novartis Pharmaceuticals Corporation
- Primary ID CLEE011X2X01B
- Secondary IDs NCI-2017-00789
- Clinicaltrials.gov ID NCT02934568